Family Med Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

2. Omega-3 fatty acids for bipolar disorder

3. Is folic acid good for everyone

4. ACS Releases Guidelines for HPV Vaccination

5. Vitamin D - A review Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA
Osteoporosis International, 10/06/09

Asche C et al. – Certain patient characteristics are predictors of physicians prescribing oral bisphosphonates. However, many patients remain untreated.

Methods

Females age 50+ years with first fracture, osteoporosis diagnosis, or BMD ≤ 2.5 (index date) were identified in Geisinger Health System electronic health record database
Treatment defined as oral bisphosphonate prescription order (risedronate sodium, ibandronate sodium, or alendronate) ≤ 90 days post-index date
Treatment rates assessed and a multivariate logistic model used to identify predictors of treatment separately for patients with fracture (FRAC) and with diagnosis or low BMD (ICD-9-BMD)

Results

FRAC group had 2,003 female patients with a mean (SD) age of 69.0 (± 11.3) years and the ICD-9-BMD group had 12,976 female patients with a mean (SD) age of 66.9 (± 10.0) years
Within 90 days of the index date of fracture, diagnosis, or low BMD score, 188 (9.4%) patients in FRAC group and 5,395 (41.6%) in ICD-9-BMD group received treatment
Treatment positively associated with age and oral corticosteroids and negatively associated with BMI and subsequent BMD in both groups
Smoking currently positively associated with treatment in ICD-9-BMD group

<< Previous
Divided by a lack of common language? - a qualitative study...

Next >>
Effects of arzoxifene on bone, lipid markers, and safety...